CHEMISTRY ENABLING DRUG DISCOVERY

11/2009



http://www.chemmedchem.org




ChemMedChem, European in origin but international in scope, deals with all aspects of drug discovery. It is co-owned by

Chemistry Publishing Society Europe (ChemPubSoc Europe) and is published by Wiley-VCH. Contributions in *ChemMedChem* cover medicinal and pharmaceutical sciences, drug design, drug development and delivery, molecular modeling, combinatorial chemistry, target validation, lead generation, and ADMET studies, that is, research from the overlapping areas between biology, chemistry, and medicine. *ChemMedChem* publishes Communications and Full Papers, as well as Reviews, Minireviews, Highlights, Concepts, Essays, Book Reviews, and occasionally Conference Reports. Authors can submit manuscripts to *ChemMedChem* online through our homepage (see over) by clicking on "Online Submission" and following the simple instructions.

Most of the articles in this issue have already appeared online in Wiley InterScience. See www.chemmedchem.org under EarlyView®

COVER PICTURE



The cover picture shows the classification, using the MQN system, of 8.4 million molecules in the public database of drug-like molecules ZINC. In analogy to the Periodic System of the Elements, in which atoms are classified by their atomic and main quantum numbers, the MQN system classifies molecules according to 42 molecular quantum numbers (MQN), defined as counts for structural features such as atoms, bonds, polar groups, and ring types. The 42-dimensional MQN space is represented as a projection in two dimensions along the first two principal components, the surface of which is color-coded by the number of cycles per molecule (blue to orange, 0 to 7 cycles). The red dots represent a family of known benzodiazepine receptor ligands. Related molecules are grouped closely in MQN space, as illustrated for diazepam and its nearest neighbors (structural formulae, MQN distance is indicated below each molecule). The MQN system provides a general and unifying concept for classifying large databases of organic molecules. For more details, see the Communication by J.-L. Reymond et al. on p. 1803 ff.

CLUSTER: Computational Medicinal Chemistry

As computer power has increased, so have the potential computational applications to practical problems. This is particularly true in the fields of pharmaceutical science and drug discovery where computational methods are used for hit and lead identification and refinement. The scope and importance of this research are exemplified in this issue's cluster. For more details, see Communications from p. 1803 to 1809 and Full Papers from p. 1859 to 1911.





PORTUGAL

SPAIN

VENSA

SISAME

SWEDEN

CHEMMEDCHEM

MASTHEAD

Editorial Board

Chairmen Giorgio Tarzia (Italy) Rainer Metternich (USA)

Members

Karl-Heinz Altmann (Switzerland) Roberto Pellicciari (Italy) Paul A. Bartlett (USA) Jeff Blaney (USA) Harren Jhoti (UK) Gerhard Klebe (Germany)

Giuseppe Ronsisvalle (Italy) Hans Ulrich Stilz (Germany) Yasuyoshi Watanabe (Japan)

International Advisory Board

Magid Abou-Gharbia (USA) Geo Adam (Switzerland) Pier Giovanni Baraldi (Italy) Francis Barth (France) Ivano Bertini (Italy) Maurizio Botta (Italy) Maria José Camarasa (Spain) Angelo Carotti (Italy) Patrick Casara (France) Gloria Cristalli (Italy) Bernd Clement (Germany) Benjamin F. Cravatt (USA) François Diederich (Switzerland)

Romano Di Fabio (Italy) Edmond Differding (Belgium) Stephen Fesik (USA) Gert Fricker (Germany) Alois Fürstner (Germany) Athanassios Giannis (Germany) William A. Goddard (USA) Pilar Goya Laza (Spain) Stephen Hanessian (Canada) George Hartman (USA) Victor Hruby (USA) Adriaan P. IJzerman (The Netherlands) Javed Iqbal (India) Hualiang Jiang (China) C. Oliver Kappe (Austria)

Kazunori Kataoka (Japan) Alan P. Kozikowski (USA) Paul Leeson (UK) Steven V. Ley (UK) Dawei Ma (China) Ulf Madsen (Denmark) Jean Martinez (France) Péter Mátyus (Hungary) Lieven Meerpoel (Belgium) Klaus Müller (Switzerland) Rolf Müller (Germany) Mark Murcko (USA) Stephen Neidle (UK) Peter Nussbaumer (Germany) Tudor I. Oprea (USA) Eckhard Ottow (Germany) Maurice Petitou (France) Paul J. Reider (USA) Ferran Sanz (Spain) Gerd Schnorrenberg (Germany) Peter G. Schultz (USA) Carlo Scolastico (Italy) Injae Shin (South Korea) Herbert Waldmann (Germany) Ralph Weissleder (USA) Hanno Wild (Germany) David A. Winkler (Australia) Li-He Zhang (China)

ChemMedChem succeeds IL FARMACO, a journal of the Società Chimica Italiana

Editor:

Peter Gölitz **Deputy Editor:** Natalia Ortúzar

Senior Associate Editor: Scott D. Williams

Managing Editor: Lisa Abel

Editorial Assistant: Bianca Davidson

Production Janine Biderman, Denis Ott Secretary: Luisa Prieto

Telephone: (+ 49) 6201-606-142

Fax: (+ 49) 6201-606-331 or -328 E-mail:

chemmedchem@wiley.com

Courier Services: Boschstraße 12 69469 Weinheim (Germany)

Regular Mail: Postfach 10 11 61 69451 Weinheim (Germany)

Homepage: http://www.chemmedchem.org

Manuscript Submission & Personal Homepage

manuscript press

http://www.manuscriptxpress.com

Subscriptions: Customer Service (ext. 400, fax: ext. 184, e-mail: service@wiley-vch.de)

Marketing: Monika Silz (ext. 458, fax: ext. 100, e-mail: msilz@wiley.com)

Advertising: Marion Schulz (ext. 565, fax: ext. 550, e-mail: mschulz@wiley.com, jspiess@wiley.com)

Copyright Permissions: Bettina Loycke (ext. 280, fax: ext. 447, e-mail: rightsde@wiley.com)

Reprint Orders: Carmen Leitner (fax: ext. 226) e-mail: chem-reprints@wiley.com

Publishers: WILEY-VCH Verlag GmbH & Co. KGaA, Postfach 10 11 61 69451 Weinheim (Germany) http://www.wiley-vch.de/

Coordinating Managing Editor: Karen J. Hindson

Publication: 12 issues in 2009

© 2009 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Further masthead information follows directly after the Table of Contents.


CONTENTS

NEWS

Spotlights on our sister journals

MINIREVIEWS

Prodrug technologies aimed at delivering nucleoside monophosphates into cells (protides) have proved to be effective in improving the therapeutic potential of antiviral and anticancer nucleosides. In the phosphoramidate protide method, developed in our laboratories, the charges of the phosphate group are fully masked to provide efficient passive cell membrane penetration, and upon entering the cell, the masking groups are enzymatically cleaved to release the phosphorylated biomolecule. This Minireview discusses the development and applications of phosphoramidate technology.



Y. Mehellou, J. Balzarini, C. McGuigan*

1779 – 1791


1776 - 1778

Aryloxy Phosphoramidate Triesters: a Technology for Delivering Monophosphorylated Nucleosides and Sugars into Cells

HIGHLIGHTS

Chemical biology for medicinal

chemistry: The nonsteroidal anti-inflammatory drug sulindac was originally developed to inhibit cyclooxygenase enzymes (COX1/2) to treat inflammation and pain. Recent studies have shown that sulindac also acts on the Wnt signaling pathway, a target relevant to cancer.




J. R. Simard, D. Rauh*

1793 – 1795

Chemical and Structural Biology to Direct the Repurposing of Sulindac

COMMUNICATIONS

C/Si switch: Twofold sila-substitution (C/Si exchange) in the RAR α -selective retinoids **1a** (AM80) and **2a** (AM580) leads to **1b** (disila-AM80) and **2b** (disila-AM580), respectively. The chemistry and biology of the C/Si pairs are reported.




EI = C: AM80 (1a) EI = SI: Disila-AM80 (1b) R. Tacke,* V. Müller, M. W. Büttner, W. P. Lippert, R. Bertermann, J. O. Daiß, H. Khanwalkar, A. Furst, C. Gaudon, H. Gronemeyer

1797 – 1802

Synthesis and Pharmacological Characterization of Disila-AM80 (Disila-tamibarotene) and Disila-AM580, Silicon Analogues of the RAR α -Selective Retinoid Agonists AM80 (Tamibarotene) and AM580 K. T. Nguyen, L. C. Blum, R. van Deursen, J.-L. Reymond*

1803 - 1805

Classification of Organic Molecules by Molecular Quantum Numbers




Classifying organic molecules using counts for simple structural features, such as atom, bond and ring types, called molecular quantum numbers (MQNs), defines a universal chemical space for analyzing large molecular databases such as ZINC and GDB. The organization of MQN space is revealed by principal component analysis (PCA), as shown for the GDB-11 database (26.4 million structures, up to 11 atoms of C, N, O, F).

S. Keppner, E. Proschak, G. Schneider, B. Spänkuch*

1806 - 1809

Identification and Validation of a Potent Type II Inhibitor of Inactive Polo-like Kinase 1




Virtual screening using a homology model of human polo-like kinase 1 (Plk1) in an inactive conformation led to the identification of a selective Plk1 inhibitor that decreases proliferation and induces apoptosis. This suggests that type II Plk1 inhibitors may be considered for the development of cancer therapeutics.

C. Xia,* W. Zhang, Y. Zhang, W. Chen, J. Nadas, R. Severin, R. Woodward, B. Wang, X. Wang, M. Kronenberg, P. G. Wang*

1810 - 1815

The Roles of 3' and 4' Hydroxy Groups in α -Galactosylceramide Stimulation of Invariant Natural Killer T Cells



NKT cell stimulation: C3'- and C4'modified α -galactosylceramide (α -GalCer) analogues show that the 3'-OH group is crucial for maintaining α -GalCer immunogenicity; any modifications at this position lead to loss of activity. However, the C4' position is less sensitive and tolerates minor modifications. Moreover, C4'-substituted analogues can induce the release of biased T_h2 cytokines.

T. N. Glasnov, K. Groschner, C. O. Kappe*

1816 – 1818

High-Speed Microwave-Assisted Synthesis of the Trifluoromethylpyrazol-Derived Canonical Transient Receptor Potential (TRPC) Channel Inhibitor Pyr3





a) 4-nitrophenylhydrazine, EtOH, MW, 160°C, 2–5 min
b) Pd/C, cyclohexene, EtOH, MW, 160°C, 2–5 min
c) R⁴CO₂H, MeCN, PCI₃, MW, 150°C, 5 min

Process intensification using controlled microwave heating allows an efficient three-step synthesis of pyrazole-based inhibitors of TRPC3 and related NFAT transcription factor regulators. Compared to the conventional protocol, a dramatic reduction in overall processing time from ~2 days to 40 min was achieved, accompanied by significantly improved product yields.


(4 examples)

CONTENTS


FULL PAPERS

No exit: Forty analogues of 3-biphenyl-5,6-dihydroimidazo[2,1-*b*]thiazole **1** were synthesized and their activities as iodide efflux inhibitors were evaluated in rat thyroid-derived cells. This study not only provided important SAR data, but has also identified a new compound with enhanced potency.

N-Phosphono derivatives and corresponding diethyl esters of 3,5-bis(benzylidene)-4-piperidones are disclosed as potent cytotoxic agents capable of reversing multi-drug resistance. As a handful of these compounds represent excellent lead structures, a number of guidelines for expanding this project have been made.



Open sesame: Enhanced activity as K_{ATP} channel openers was found in benzothiadiazine-1,1-dioxides with cycloaliphatic side chains in the position 3, relative to the parent compound, diazoxide (R=H). High selectivity was reached with nonpolar globular substituents (R=1-adamantyl): the affinity for the SUR2B/Kir6.1 ion channel surpasses that for SUR/Kir6.2 receptor by more than two orders of magnitude.




40 analogues

N. Lecat-Guillet, Y. Ambroise*

1819 – 1830

Synthesis and Evaluation of Imidazo[2,1-*b*]thiazoles as lodide Efflux Inhibitors in Thyrocytes



S. Das, U. Das, P. Selvakumar, R. K. Sharma, J. Balzarini, E. De Clercq, J. Molnár, J. Serly, Z. Baráth, G. Schatte, B. Bandy, D. K. J. Gorecki, J. R. Dimmock*

1831 – 1840

3,5-Bis(benzylidene)-4-oxo-1phosphonopiperidines and Related Diethyl Esters: Potent Cytotoxins with Multi-Drug-Resistance Reverting Properties

M. Farhad, J. Q. Yu, P. Beale, K. Fisher, F. Huq*

1841 – 1849

Studies on the Synthesis and Activity of Three Tripalladium Complexes Containing Planaramine Ligands

S. Lachenicht, A. Fischer, C. Schmidt, M. Winkler, A. Rood, H. Lemoine, M. Braun*


1850 – 1858

Synthesis of Modified 4*H*-1,2,4-Benzothiadiazine-1,1-dioxides and Determination of their Affinity and Selectivity for Different Types of K_{ATP} Channels

B. Nisius, J. Bajorath*

1859 - 1863

Molecular Fingerprint Recombination: Generating Hybrid Fingerprints for Similarity Searching from Different Fingerprint Types




Fingerprint recombination is introduced as a methodology to generate hybrid fingerprints from original fingerprints of distinct design. Hybrid fingerprints combine preferred bit subsets from their parental fingerprints and emphasize compound class-specific features during similarity searching, which leads to consistent improvements in search performance. This new fingerprint design strategy is generally applicable to fingerprint representations where individual bit positions are associated with defined chemical information.

L. Peltason, Y. Hu, J. Bajorath*

1864 - 1873

From Structure–Activity to Structure– Selectivity Relationships: Quantitative Assessment, Selectivity Cliffs, and Key Compounds




Selectivity cliffs: Network-like similarity graphs are used to organize similarity relationships and selectivity distributions within collections of compounds that are active against multiple targets. Shown here is a network region that contains compounds with different selectivities that are selectivity cliff markers (identified by red and green nodes) and highlights substituents that determine selectivity.

E. Luttmann, J. Ludwig, A. Höffle-Maas, M. Samochocki, A. Maelicke, G. Fels*

1874 – 1882

Structural Model for the Binding Sites of Allosterically Potentiating Ligands on Nicotinic Acetylcholine Receptors




Galanthamine acts as an allosteric potentiating ligand at nicotinic acetylcholine receptors, thereby opening a new approach for the symptomatic treatment of Alzheimer's disease. Amino acids essential for the allosteric effect of galanthamine were identified by molecular modeling and verified by sitedirected mutagenesis and electrophysiological experiments.

I. K. Pajeva, C. Globisch, M. Wiese*

1883 – 1896

Combined Pharmacophore Modeling, Docking, and 3D QSAR Studies of ABCB1 and ABCC1 Transporter Inhibitors




Selective and dual inhibitors of the ABCB1 (P-gp) and ABCC1 (MRP1) transporters were studied by pharmacophore modeling, docking into the P-gp binding cavity, and 3D QSAR to describe the binding preferences of the proteins and to identify the similarities and differences in their interactions.

ChemMedChem 2009, 4, 1767-1774

CONTENTS

A series of small-molecule activators of P-glycoprotein (P-gp) based on an imidazo[1,2-*a*]benzimidazole lead structure were synthesized and characterized with various functional assays. Although all these compounds are structurally related, a small subset inhibited P-gp.




K. Sterz, L. Möllmann, A. Jacobs, D. Baumert, M. Wiese*

1897 – 1911

Activators of P-glycoprotein: Structure-Activity Relationships and Investigation of their Mode of Action


A disruptive influence: We studied the antimitotic activity of a series of new *iso*combretastatin derivatives with B-ring modifications. We selected *iso*combretastatin analogues *iso*CA-4, *iso*-NH₂CA-4 and *iso*FCA-4 as lead compounds for their high antitumor activity.



A. Hamze, A. Giraud, S. Messaoudi, O. Provot, J.-F. Peyrat, J. Bignon, J.-M. Liu, J. Wdzieczak-Bakala, S. Thoret, J. Dubois, J.-D. Brion, M. Alami*

1912 – 1924

Synthesis, Biological Evaluation of 1,1-Diarylethylenes as a Novel Class of Antimitotic Agents




Glutamate analogues 1–3 are hybrid structures of the previously reported analogues **4–8**. These three analogues were investigated at the iGluRs and EAAT1–3, and results of our in silico studies explain the differences in their pharmacological profiles, providing further insight into the SAR for iGluR and EAAT ligands. L. Bunch,* D. S. Pickering, T. Gefflaut, V. Vinatier, V. Helaine, A. Amir, B. Nielsen, A. A. Jensen

1925 – 1929

4,4-Dimethyl- and Diastereomeric 4-Hydroxy-4-methyl- (2S)-Glutamate Analogues Display Distinct Pharmacological Profiles at Ionotropic Glutamate Receptors and Excitatory Amino Acid Transporters

Bioorganometallic antibacterial

agents: The synthesis of Cr organometallics based on the lead structure of the new antibiotic platensimycin is described. Compounds containing a (η^{6} pentamethylbenzene)Cr(CO)₃ moiety are significantly more active than other metal-containing analogues and also the metal-free derivatives, and exhibited antibacterial activity against the Grampositive *B. subtilis* but not against Gramnegative *E. coli.*



M. Patra, G. Gasser, A. Pinto, K. Merz, I. Ott, J. E. Bandow, N. Metzler-Nolte*


1930 – 1938

Synthesis and Biological Evaluation of Chromium Bioorganometallics Based on the Antibiotic Platensimycin Lead Structure

K. Ziegler, D. R. J. Hauser, A. Unger, W. Albrecht, S. A. Laufer*

1939 – 1948

2-Acylaminopyridin-4-ylimidazoles as p38 MAP Kinase Inhibitors: Design, Synthesis, and Biological and Metabolic Evaluations



Novel 1,2,4,5-tetrasubstituted imidazole derivatives were prepared. They were characterized not only for their ability to inhibit p38 MAP kinase and to modulate cytokine release in human whole blood, but also for their metabolic stability.

D. Selwood 1949

L. Prokai 1950

A video clip is available as Supporting Information

on the WWW (see article for access details).

Supporting information on the WWW (see article for access details).

* Author to whom correspondence should be addressed.

BOOKS

The Cannabinoid Receptors • P. H. Reggio (Ed.) Cancer Proteomics: From Bench to Bedside • S. S. Daoud (Ed.)

Author Index 1952 Preview 1955

All the Tables of Contents may be found on the WWW under: http://www.chemmedchem.org

Keyword Index 1953

Issue 10, 2009, was published online on September 28, 2009.

